Prophylactic Human Vaccine MarketSize and Trends

Prophylactic Human Vaccine Market – Drivers

Increasing number of pipeline studies and rising involvement of key players for vaccine development is expected to propel growth of the prophylactic human vaccine market during the forecast period. For instance, in October 2018, CureVac AG, announced to initiate dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This will enable vaccinated individual's own cells to produce RABV-G protein, by which immune response gets triggered. This study is estimated to complete in January 2021.

Moreover, in October 2018, Valneva SE announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. It is designed for prophylactic, active, single-dose immunization against Chikungunya in humans. The vaccine aims for long-lasting protection and an anticipated safety profile similar to other approved vaccines for active immunization in adults and children.

Furthermore, rising initiatives by various scientists to develop innovative solutions to fight against infectious diseases is expected to drive growth of the market. For instance, VBI Vaccines Inc., in September 2018, announced formation of three Scientific and Clinical Advisory Boards (SABs) comprising leading experts in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). This collaboration is expected to propel growth of the market, owing to enhanced vaccine development.